C
39.70
0.06 (0.15%)
| Previous Close | 39.64 |
| Open | 39.60 |
| Volume | 783,000 |
| Avg. Volume (3M) | 2,642,993 |
| Market Cap | 6,142,739,968 |
| Price / Sales | 358.74 |
| Price / Book | 12.59 |
| 52 Weeks Range |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bearish | Bullish |
AIStockmoo Score
-0.8
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 94.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 31 Mar 2026 | 9,961,789 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |